온코닉테라퓨틱스
13,770KRWMarket close of 10/21 (Wed)
Up +1.32%+180KRWMarket close of 10/21 (Wed)
Preliminary value right after the close — replaced by official KRX data tomorrow morningClose of 10/22 (Thu)13,070KRWDown -5.08%
Preliminary · just after the close · replaced by official KRX data tomorrow morning
- Open
- 13,840
- High
- 14,120
- Low
- 13,670
- Day range
- Day range low 13,670 high 14,120, open 13,840, close 13,770, previous close 13,590
- Volume
- 9×10K shares
- 1.2B KRW 0.45× the 20-session average
Market close of 10/21 (Wed)
Where it sits in the 1-year range
25%25% of the way up from the lowest close in 1 year (251 sessions) · -47.6% from the high
Usual range
Nothing unusual in the 5 checked items
Free · no sign-inSource from 2021-05-17
Points to check
- Earningsnot verifiedOutside financial data coverage, so not verified
- Daily moveusual range+1.32%+1.32%, 0.5× the usual (20-session average ±2.49%)That day +1.32% · usual ±2.49% · large-move threshold ±5.0%
- Trading valueusual range0.4×1.2B KRW, 0.4× the 20-session average0.45× the 20-session average · check threshold 3×
The other 3 are within the usual range
- Recent filings0Last 14 days
- Foreign & institutional+2.5B KRWusual range
- Data date10/21 (Wed)Market close
See the full check report
Same sector · 바이오 R&D
Up +3.03%· 33 of 64 stocks up, preferred shares excluded · trading value 215.2B KRW
| Stock | 20D | Change | Trading value |
|---|---|---|---|
| 알테오젠 | Close over the last 20 sessions -5.5% | Up +3.90% | 60.7B KRW |
| 올릭스 | Close over the last 20 sessions -6.4% | Up +9.53% | 26.1B KRW |
| 디앤디파마텍 | Close over the last 20 sessions -6.0% | Up +6.65% | 22.0B KRW |
| 리가켐바이오 | Close over the last 20 sessions -14.3% | Up +2.00% | 12.9B KRW |
| 프로티나 | Close over the last 20 sessions +35.7% | Up +7.23% | 11.0B KRW |
Schedule
- Next data 10/23 (Fri) after 08:50
Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 85% of trading value, about 92% of market capitalisation. Coverage status →
For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.